Prostate Cancer
AstraZeneca, Alchemab Partner on Prostate Cancer Immunotherapy Research
UK-based Alchemab will use its platform to sequence the antibody repertoires of prostate cancer patients treated within an AstraZeneca immunotherapy trial.
FDA Accepts IND for Clarity Pharmaceuticals' Prostate Cancer Radiopharmaceutical
Clarity will begin a Phase I/II trial of its diagnostic and therapeutic product pairing to treat PSMA-positive, metastatic prostate cancer.
The 20-year study showed the test provided an accurate assessment of the risk of long-term metastases and mortality for patients with localized prostate cancer.Â
Tango Therapeutics to Go Public on Nasdaq Through SPAC
The combined company is expected to receive $353 million in gross proceeds, which will help advance several of Tango's precision oncology drug candidates.
AACR Study Tests Immunogenic Signature in Prostate Cancer Patients on Dual Checkpoint Inhibitor
Although the trial didn't hit its prespecified response target to Opdivo and Yervoy, researchers will further study the promising signals they saw in biomarker groups.